Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8: early-phase trial registry
5 of 9 indexed Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 5 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8: 9 US clinical trials tracked, 5 recruiting.
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition clinical-stage-iv-esophageal-adenocarcinoma-ajcc-v8
OPEN 5 | RECR 56% | LATE 2 | EARLY 4 | RANK #1916 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Advanced Colorectal Cancer (56% recruiting · 9 trials)
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 lists 5 open slots (56% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 is recruiting above its size-band peers.
5 of 9 indexed trials (55.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 research.
National Cancer Institute (NCI) accounts for 3 of 9 trials (33.3%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 enrolment sits around 224 participants.
Median target enrolment is 224 among the 9 trials that report a genuine target (sentinel values excluded). 4 of those (44.4%) plan for fewer than 100 participants.
-
Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 research is mostly interventional.
8 interventional and 1 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute (NCI)
NCT04314401
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Alliance for Clinical Trials in Oncology
NCT05677490
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
National Cancer Institute (NCI)
NCT06203600
Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer
University of Washington
NCT05911243
Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma
Roswell Park Cancer Institute
NCT05651594
Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
M.D. Anderson Cancer Center
NCT05038254
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
ECOG-ACRIN Cancer Research Group
NCT04248452
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers
National Cancer Institute (NCI)
NCT04460937
Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma
M.D. Anderson Cancer Center
NCT03395847
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 page
9 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 condition card totals 9 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.